Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR) in combination with platinum-based chemotherapy has been for the decade standard of care for the treatment of head and neck squamous cell carcinomas (HNSCC) patients in the first-line recurrent and/or metastatic s...
Main Authors: | Edith Borcoman, Gregoire Marret, Christophe Le Tourneau |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/11/2573 |
Similar Items
-
Successful treatment of recurrent unresectable squamous cell carcinoma of the head and neck using pembrolizumab
by: A. M. Mudunov, et al.
Published: (2019-04-01) -
Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
by: Christian Borel, et al.
Published: (2020-09-01) -
Tumor microenvironment and immune-related therapies of head and neck squamous cell carcinoma
by: Yixiao Qin, et al.
Published: (2021-03-01) -
Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
by: Miren Taberna, et al.
Published: (2019-05-01) -
Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
by: Ronan W. Hsieh, et al.
Published: (2021-09-01)